WEBVTT

1
00:00:00.300 --> 00:00:01.860
- Amgen is getting closer

2
00:00:01.860 --> 00:00:05.610
to challenging the weight loss
drug duopoly of Novo Nordisk,

3
00:00:05.610 --> 00:00:07.620
the maker of Ozempic and Wegovy,

4
00:00:07.620 --> 00:00:10.830
and Eli Lilly, which produces Zep bound.

5
00:00:10.830 --> 00:00:13.020
The pharma company announced today

6
00:00:13.020 --> 00:00:16.050
that it has begun too
late stage clinical trials

7
00:00:16.050 --> 00:00:18.810
for its experimental
weight loss drug meritide.

8
00:00:18.810 --> 00:00:21.540
If successful Meritide
could disrupt the market

9
00:00:21.540 --> 00:00:24.900
by offering a less frequent
dosing regimen than the current

10
00:00:24.900 --> 00:00:26.970
weekly injections on the market.

11
00:00:26.970 --> 00:00:29.790
The drug has been tested as
a once a month treatment,

12
00:00:29.790 --> 00:00:32.460
as well as with dosing
intervals of every other month

13
00:00:32.460 --> 00:00:33.990
and once every three months.

14
00:00:33.990 --> 00:00:36.390
Amgen's executive Vice
President of Research

15
00:00:36.390 --> 00:00:39.330
and Development j Bradner,
shared key details

16
00:00:39.330 --> 00:00:42.420
of the new trials Wednesday
morning at TD Cohen's Annual

17
00:00:42.420 --> 00:00:43.740
Healthcare Conference.

18
00:00:43.740 --> 00:00:47.610
The two trials will enroll
about 4,500 patients In total,

19
00:00:47.610 --> 00:00:51.210
one study will recruit 3,500
participants that are obese

20
00:00:51.210 --> 00:00:55.470
or overweight, while the
other will include 999 people

21
00:00:55.470 --> 00:00:57.630
who are both obese or overweight,

22
00:00:57.630 --> 00:00:59.640
and have type two diabetes.

23
00:00:59.640 --> 00:01:01.980
The primary objective of both studies is

24
00:01:01.980 --> 00:01:05.580
to assess the percentage
of weight loss at 72 weeks.

25
00:01:05.580 --> 00:01:08.730
Amgen will test three
dose levels, low, medium,

26
00:01:08.730 --> 00:01:11.280
and high, starting
patients at a lower dose

27
00:01:11.280 --> 00:01:14.700
and gradually increasing it
to the target doses according

28
00:01:14.700 --> 00:01:16.650
to clinical trials.gov.

29
00:01:16.650 --> 00:01:20.280
The studies are set to begin
officially on March 17th

30
00:01:20.280 --> 00:01:23.280
and are expected to
conclude in early 2027.